Sabby Volatility Fund Divests All Voting Shares in Bone Biologics
Ticker: BBLGW · Form: SC 13G/A · Filed: Jan 2, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | SC 13G/A |
| Filed Date | Jan 2, 2024 |
| Risk Level | medium |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: institutional-ownership, divestment, amendment, ownership-change
TL;DR
**Sabby Volatility Fund dumped all its voting shares in BBLG, watch out!**
AI Summary
Sabby Volatility Warrant Master Fund, Ltd. has filed an amended SC 13G/A for Bone Biologics Corp (BBLG), indicating a change in their beneficial ownership as of December 31, 2023. The filing shows that Sabby Volatility Warrant Master Fund, Ltd. now holds 0 shares with sole voting power, a significant decrease from their previous holdings. This matters to investors because a major institutional investor has completely divested their voting shares, which could signal a loss of confidence in the company's future prospects or a strategic portfolio reallocation.
Why It Matters
This filing reveals a major institutional investor, Sabby Volatility Warrant Master Fund, Ltd., has reduced its sole voting power in Bone Biologics Corp to zero, potentially signaling a lack of confidence or a shift in investment strategy.
Risk Assessment
Risk Level: medium — The complete divestment of voting shares by an institutional investor like Sabby Volatility Warrant Master Fund, Ltd. could indicate underlying concerns about Bone Biologics Corp's future performance.
Analyst Insight
A smart investor would investigate the reasons behind Sabby Volatility Warrant Master Fund, Ltd.'s complete divestment of voting shares in Bone Biologics Corp and consider if this signals fundamental issues before making any investment decisions.
Key Numbers
- 0 — Sole Voting Power Shares (Number of shares with sole voting power held by Sabby Volatility Warrant Master Fund, Ltd. as of December 31, 2023.)
- 098070303 — CUSIP Number (Identifier for Bone Biologics Corp's Common Stock.)
- December 31, 2023 — Date of Event (The date that triggered the requirement for this filing.)
Key Players & Entities
- Sabby Volatility Warrant Master Fund, Ltd. (company) — reporting person and institutional investor
- Bone Biologics Corp (company) — subject company (issuer) of the securities
- Sabby Management, LLC (company) — entity that filed the SC 13G/A
- Cayman Islands (place) — place of organization for Sabby Volatility Warrant Master Fund, Ltd.
Forward-Looking Statements
- Bone Biologics Corp's stock price may experience downward pressure due to the institutional divestment. (Bone Biologics Corp) — medium confidence, target: Q1 2024
- Other institutional investors might re-evaluate their positions in Bone Biologics Corp following this filing. (Institutional Investors) — low confidence, target: Q1 2024
FAQ
What is the primary purpose of this SC 13G/A filing?
The primary purpose of this SC 13G/A filing is to amend a previous Schedule 13G, specifically to disclose a change in beneficial ownership of Common Stock in Bone Biologics Corp by Sabby Volatility Warrant Master Fund, Ltd. as of December 31, 2023.
Which entity is the 'Reporting Person' in this filing?
The 'Reporting Person' in this filing is Sabby Volatility Warrant Master Fund, Ltd., as indicated in Item 1 of the cover page.
What is the reported sole voting power of the Reporting Person?
The reported sole voting power of Sabby Volatility Warrant Master Fund, Ltd. is 0 shares, as stated in Item 5 of the cover page.
What is the CUSIP number for the securities discussed in this filing?
The CUSIP number for the Common Stock of Bone Biologics Corp is 098070303, as listed on the cover page of the filing.
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed under Rule 13d-1(c), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 2, 2024 regarding Bone Biologics Corp (BBLGW).